In trials of Wegovy, up to 40% of weight loss was from a decrease in lean or fat-free mass, rather than excess fat. These experimental medicines are still a few years from possible approval. Veru ...

Veru Veru’s oral drug, enobosarm, targets the androgen hormones that play a role in body development and reproductive health. In a mid-stage study, patients who received the drug along with Wegovy ...

The Food and Drug Administration on Friday said the shortage of Novo Nordisk's weight-loss and diabetes drugs Wegovy and Ozempic is resolved, a move that could limit the availability of cheaper ...

Veru's enobosarm is designed to be used in combination with GLP-1 agonist-based obesity drugs – such as Novo Nordisk's blockbuster Wegovy (semaglutide) – to reduce the loss of lean muscle mass ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study ... 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage ...

Feb 21 (Reuters) - The U.S. Food and Drug Administration said on Friday there was no longer a shortage of Novo Nordisk's NOVOb.CO popular weight-loss and diabetes drugs, Wegovy and ...

MIAMI, FL, Feb. 04, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ ... patients receiving semaglutide (Wegovy®). The primary endpoint was total lean body mass, and the key secondary endpoints ...

Veru had a pre-IND meeting with the FDA Division ... In fact, the safety section of the package insert for Wegovy has been updated based on the recently reported SELECT cardiovascular outcomes ...

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...